[go: up one dir, main page]

CR9064A - Uso de epotilonas en el tratamiento de metastasis en hueso y tumores o tipos de cancer en hueso - Google Patents

Uso de epotilonas en el tratamiento de metastasis en hueso y tumores o tipos de cancer en hueso

Info

Publication number
CR9064A
CR9064A CR9064A CR9064A CR9064A CR 9064 A CR9064 A CR 9064A CR 9064 A CR9064 A CR 9064A CR 9064 A CR9064 A CR 9064A CR 9064 A CR9064 A CR 9064A
Authority
CR
Costa Rica
Prior art keywords
bone
cancer
tumors
types
treatment
Prior art date
Application number
CR9064A
Other languages
English (en)
Inventor
Jens Hoffmann
Ulrich Klar
Hubertus Pietsch
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34928830&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR9064(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of CR9064A publication Critical patent/CR9064A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

La presente invencion se refiere al uso de epotilonas en el tratamiento de metastasis en el hueso y tumores o tipos de cancer en hueso, mas en particular para tratar, prevenir o aliviar las metastasis en un paciente de cancer.
CR9064A 2004-09-24 2007-04-19 Uso de epotilonas en el tratamiento de metastasis en hueso y tumores o tipos de cancer en hueso CR9064A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04090377A EP1640004A1 (en) 2004-09-24 2004-09-24 Use of epothilones in the treatment of bone metastases and bone tumors or cancers

Publications (1)

Publication Number Publication Date
CR9064A true CR9064A (es) 2007-10-01

Family

ID=34928830

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9064A CR9064A (es) 2004-09-24 2007-04-19 Uso de epotilonas en el tratamiento de metastasis en hueso y tumores o tipos de cancer en hueso

Country Status (21)

Country Link
EP (2) EP1640004A1 (es)
JP (1) JP2008514569A (es)
KR (1) KR20070054214A (es)
CN (1) CN101065126A (es)
AR (1) AR051035A1 (es)
AU (1) AU2005287477A1 (es)
BR (1) BRPI0516080A (es)
CA (1) CA2580215A1 (es)
CR (1) CR9064A (es)
EC (1) ECSP077390A (es)
GT (1) GT200500267A (es)
IL (1) IL181785A0 (es)
MX (1) MX2007003503A (es)
NO (1) NO20072099L (es)
PA (1) PA8646201A1 (es)
PE (1) PE20060695A1 (es)
RU (1) RU2007115162A (es)
TW (1) TW200626150A (es)
UY (1) UY29136A1 (es)
WO (1) WO2006032537A2 (es)
ZA (1) ZA200703306B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1930004A1 (en) * 2006-12-08 2008-06-11 Bayer Schering Pharma Aktiengesellschaft Use of epothilones in the treatment of osteoporosis and related diseases

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6605599B1 (en) * 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
FR2775187B1 (fr) * 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
PT1140944E (pt) * 1998-12-22 2004-01-30 Novartis Pharma Gmbh Derivados de epotilona e sua utilizacao como agentes antitumorais
PE20010116A1 (es) * 1999-04-30 2001-02-15 Schering Ag Derivados de 6-alquenil-, 6-alquinil- y 6-epoxi-epotilona, procedimientos para su preparacion
EP2289549A3 (en) * 1999-10-01 2011-06-15 Immunogen, Inc. Immunoconjugates for treating cancer
JP2004508810A (ja) * 2000-04-28 2004-03-25 コーサン　バイオサイエンシーズ，　インコーポレイテッド ポリケチドの生成
UA75365C2 (en) * 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
AU2002338336A1 (en) * 2001-04-03 2002-10-21 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same
TWI315982B (en) * 2001-07-19 2009-10-21 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
WO2003077903A1 (en) * 2002-03-12 2003-09-25 Bristol-Myers Squibb Company C12-cyano epothilone derivatives
SI1503756T1 (sl) * 2002-05-01 2010-01-29 Novartis Ag Epotilonski derivat za zdravljenje hepatoma in drugih rakavih bolezni
EP1581218A1 (en) * 2002-12-05 2005-10-05 Schering AG Epothilone analogs for site specific delivery in the treatment of proliferative diseases
GB0305928D0 (en) * 2003-03-14 2003-04-23 Novartis Ag Organic compounds
EP1475105A1 (en) * 2003-05-09 2004-11-10 Schering AG Bone localising radiopharmaceutical and tubulin-interacting compound combinatorial radiotherapy
MXPA05013958A (es) * 2003-06-27 2006-02-24 Novartis Ag Tratamiento de cancer con epotilona.
MXPA06002393A (es) * 2003-09-02 2006-06-20 Novartis Ag Tratamiento de cancer con epotilomas.

Also Published As

Publication number Publication date
TW200626150A (en) 2006-08-01
PA8646201A1 (es) 2006-11-09
GT200500267A (es) 2006-06-06
EP1809281A2 (en) 2007-07-25
ZA200703306B (en) 2010-06-30
MX2007003503A (es) 2007-08-17
EP1640004A1 (en) 2006-03-29
CN101065126A (zh) 2007-10-31
UY29136A1 (es) 2006-04-28
RU2007115162A (ru) 2008-11-20
ECSP077390A (es) 2007-05-30
WO2006032537A2 (en) 2006-03-30
NO20072099L (no) 2007-04-23
KR20070054214A (ko) 2007-05-28
JP2008514569A (ja) 2008-05-08
WO2006032537A3 (en) 2006-05-04
IL181785A0 (en) 2007-07-04
CA2580215A1 (en) 2006-03-30
PE20060695A1 (es) 2006-08-03
AR051035A1 (es) 2006-12-13
AU2005287477A1 (en) 2006-03-30
BRPI0516080A (pt) 2008-08-19

Similar Documents

Publication Publication Date Title
MX2007014132A (es) Compuestos de diarilhidantoina.
CY1109741T1 (el) Sns-595 και μεθοδοι χρησης αυτου
PA8637201A1 (es) Difenilimidazopirimidina e-imidazol aminas como inhibidores de la b-secretasa
CL2007002382A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento del cancer a la piel.
PA8637301A1 (es) Derivados de amino-5, 5-difenilimidazolona para la inhibicion de la b-secretasa
EA201300242A1 (ru) Фармацевтические композиции, содержащие замещенные ациланилиды
DK1853250T3 (da) Kombinationer og måder til indgivelse af terapeutiske midler og kombinationsterapi
GT200600092A (es) Alargar el tiempo hasta la progresion de la enfermedad o la supervivencia de los pacientes de cancer
NO20091661L (no) Anvendelse av pegylert IL-10 for a behandle kreft
MXPA05013977A (es) Metodos y composiciones para tratar enfermedades relacionadas con amiloide.
UY31484A1 (es) Piperidinas heteroaril-sustituidas
TW200509892A (en) Novel aminobenzophenone compounds
BRPI0514721A (pt) uso de compostos de peptìdeos para tratar dor de cáncer ósseo, dor induzida por quimioterapia e nucleosìdeo
SE0301650D0 (sv) Novel compounds
EA200971067A1 (ru) Триазолиламинопиримидиновые соединения
EP1789064A4 (en) ENHANCED ANTICANCER TREATMENT
BRPI0615141A2 (pt) inibidores pentacìclicos de quinase
NO20053903D0 (no) Nukleotidlipidesterderivater.
EA200801425A1 (ru) Диазепиноны
CR9064A (es) Uso de epotilonas en el tratamiento de metastasis en hueso y tumores o tipos de cancer en hueso
ATE399532T1 (de) Medizinische seife
DE602006013009D1 (de) Pharmazeutische zusammensetzung von mahanin zur behandlung von prostatakrebs
MXPA05009718A (es) Uso de un fibrato y orlistato para el tratamiento de obesidad.
TNSN06147A1 (en) Use of cathepsin k inhibitors for treating of severe bone loss diseases
EP1654537A4 (en) TSSK4: A HUMAN TESTISS-SPECIFIC SERIN / THREONIN KINASE

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)